Skip to content

CG Oncology CGON Inventories

Inventories at other companies

Pfizer logo
PfizerPFE
$2.46B-11.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.58B+15.2%
Gilead Sciences logo
Gilead SciencesGILD
$2.42B+20.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$18.86M+123%
Exelixis logo
ExelixisEXEL
$63.91M-11.2%
Biogen logo
BiogenBIIB
$139.5M+18.8%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.8B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's inventories?
CG Oncology (CGON) reported inventories of $1.49M in Q1 2026.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.